Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy

13 november 2026 uppdaterad av: MultiValent Biotherapies, Inc.

An Open-Label, Non-randomized, Multi-Center Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand Drug Conjugate MVB-101 Injected Into the Prostate of Patients With Localized Cancer of the Prostate Who Are Scheduled for Prostatectomy

This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dose-expansion design at one or more selected dose levels to further characterize safety and preliminary efficacy. Participants will undergo safety, pharmacokinetic, multiparametric magnetic resonance imaging, pathological, prostate-specific antigen, and patient-reported outcome assessments.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Detaljerad beskrivning

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen (PSMA) and folate receptor alpha (FR-alpha) and carrying monomethyl auristatin E (MMAE). MVB-101 will be administered by direct injection into the prostate under transrectal ultrasound guidance, at a fixed total injection volume of 10 mL (5 mL per lobe), once per week for 4 weeks.

Part A will enroll up to 30 participants. Planned dose levels are 1, 2, 4, and 8 mg per dose. The dose-limiting toxicity evaluation period is Day 1 through Day 29. Accelerated titration rules will be applied to the first two dose levels, and an i3+3 design will guide dose selection. Higher, lower, or intermediate dose levels may be added based on emerging data and Safety Monitoring Committee recommendations. The recommended Phase 2 dose may be the same as or lower than the maximum tolerated dose.

Part B will enroll up to 29 participants per dose group at one or more selected dose levels and will use a Simon two-stage design to better estimate the recommended Phase 2 dose and further characterize safety and preliminary efficacy.

The study includes screening, treatment, safety follow-up approximately 28 days after the last dose, post-treatment multiparametric MRI and PSA assessment, and planned radical prostatectomy at approximately Day 90 (12 weeks). If radical prostatectomy is not performed, a post-treatment prostate biopsy will be obtained as close as possible to the planned prostatectomy date. End of study occurs after completion of safety follow-up, post-treatment MRI and PSA assessment, and prostatectomy or post-treatment biopsy.

Studietyp

Interventionell

Inskrivning (Beräknad)

60

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  • Signed informed consent form.
  • Understands the obligation and is capable of attending all follow-up visits.
  • Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months before the first dose.
  • Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.
  • Gleason Grade Group 1 with at least one high-risk feature, or Grade Group 2, 3, or 4. High-risk features for Grade Group 1 are PSA density >0.2 ng/mL/cc, PI-RADS 4 or 5, lesion >1.0 cm, lesion volume >0.4 cc, or risk of extraprostatic extension evidenced by capsular abutment or bulge.
  • Prostate-specific antigen 20 ng/mL or less.
  • Eastern Cooperative Oncology Group performance status 0 or 1.
  • Adequate bone marrow and organ function.
  • Sexually active participants agree to use barrier protection during treatment and for 1 month after the last MVB-101 dose.

Exclusion Criteria:

  • Any prior treatment for prostate cancer, except prior active surveillance is permitted.
  • More than 10 mg/day of systemic steroids within 28 days before signing informed consent.
  • Prior exposure to auristatin, an auristatin derivative, or a similar molecule.
  • Prior or concurrent malignancy whose natural history or treatment could interfere with or affect MVB-101 safety or efficacy assessments.
  • Prostatic calcifications.
  • Inability to undergo MRI scanning for any reason, including claustrophobia or implanted devices.
  • Major surgery within 4 weeks before first dose or planned during the study, other than prostatectomy.
  • Toxicity attributed to prior anticancer therapy, other than alopecia and fatigue, not resolved to Grade 1 or baseline before first dose.
  • Poorly controlled concurrent disease, including diabetes or hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
  • Within 12 months before enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, or NYHA class III or IV congestive heart failure.
  • History of clinically significant lung disease, including interstitial pneumonia, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis, or suspected disease on screening imaging.
  • Active bleeding disorder or other history of Grade 3 or higher hemorrhage within 4 weeks before first dose.
  • Need for oral vitamin K antagonist anticoagulant therapy. Low-dose anticoagulants to maintain central venous access patency or prevent deep venous thrombosis and therapeutic low-molecular-weight heparin are permitted.
  • Deep vein thrombosis or pulmonary embolism within 6 months before first dose.
  • Active infection requiring intravenous antibiotics within 1 week before first dose.
  • Uncontrolled HIV, known AIDS, chronic hepatitis B, occult hepatitis B, or hepatitis C.
  • Current or anticipated need for a strong CYP3A4 inhibitor or inducer. Prior use requires a washout of 21 days or 5 half-lives, whichever is longer, before first dose.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part A: MVB-101 1 mg

MVB-101 1 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Experimentell: Part A: MVB-101 2 mg

MVB-101 2 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Experimentell: Part A: MVB-101 4 mg

MVB-101 4 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Experimentell: Part A: MVB-101 8 mg

MVB-101 8 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Experimentell: Part B: MVB-101 Dose Expansion

MVB-101 at one or more selected dose levels by intraprostatic injection once weekly for 4 weeks. Other schedules may also be explored.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Treatment-emergent adverse events
Tidsram: From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)

Number and percentage of participants with treatment-emergent adverse events, treatment-related adverse events, serious adverse events, and clinically significant changes in vital signs, physical examinations, electrocardiogram (ECG) and clinical laboratory tests, graded using NCI CTCAE version 6.0.

From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
Dose-limiting toxicities
Tidsram: Day 1 through Day 29

Number and percentage of participants with a dose-limiting toxicity, assessed according to protocol-defined criteria using NCI CTCAE version 6.0.

Day 1 through Day 29
Maximum tolerated dose
Tidsram: Through completion of Part A dose escalation, up to 12 months

Maximum tolerated dose of intraprostatic MVB-101 determined from dose-limiting toxicities and cumulative safety data under the i3+3 design.

Through completion of Part A dose escalation, up to 12 months
Recommended Phase 2 dose
Tidsram: Through completion of dose escalation and applicable dose-expansion, up to 18 months

Recommended Phase 2 dose of intraprostatic MVB-101 based on safety, tolerability, pharmacokinetics, and available efficacy data.

Through completion of dose escalation and applicable dose-expansion, up to 18 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacokinetic parameters of MVB-101 and MMAE
Tidsram: Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose

Plasma concentration-time analysis will be performed using PK concentration values over time.

Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
Pathological response in excised prostate tissue
Tidsram: At prostatectomy or post-treatment biopsy, approximately Day 90

Number and percentage of participants with persistence or absence of the dominant index prostate cancer lesion or any lesion on pathological examination of prostatectomy tissue; post-treatment multicore biopsy is used if planned prostatectomy is not performed.

At prostatectomy or post-treatment biopsy, approximately Day 90
Radiologic response by multiparametric MRI
Tidsram: Baseline and approximately 10 days, but no more than 14 days, before prostatectomy

Number and percentage of participants with persistence or absence of baseline prostate cancer lesions on post-treatment multiparametric MRI.

Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
International Prostate Symptom Score
Tidsram: Baseline through safety follow-up (approximately Day 50)

Observed values and change from baseline in International Prostate Symptom Score (IPSS). IPSS score values between 0-5 with lower scores indicating better performance/ improvement.

Baseline through safety follow-up (approximately Day 50)
International Index of Erectile Function-5
Tidsram: Baseline through safety follow-up (approximately Day 50)

Observed values and change from baseline in International Index of Erectile Function-5 (IIEF-5). IIEF-5 is scored with values 1-5 with higher scores indicating better performance/ improvement.

Baseline through safety follow-up (approximately Day 50)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Stephen Snowdy, PhD, MultiValent Biotherapies, Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 augusti 2026

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 mars 2028

Studieregistreringsdatum

Först inskickad

5 november 2026

Först inskickad som uppfyllde QC-kriterierna

13 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera